penny stock market


Poor Caterpillar (CAT). Everything had been looking up for the company, and then suddenly it wasn’t. Does that make it a perfect time for an upgrade?

Agence France-Presse/Getty Images

Caterpillar had rebounded with the global economy and as part of the Trump trade, helping to push its shares up 25% over the past 12 months. Its shares, however, have dropped 5.3% during the past month of trading, after the Fed’s raided its headquarters amid accounting questions.

It’s in this environment that Tigress Financials’ Ivanm Feinseth upgrades Caterpillar to Neutral from Underperform, citing both the “opportunity and uncertainty” surrounding the company:


CAT is best positioned to gain from the Trump Administrations focus on infrastructure improvements. However, global economic headwinds and the negative trend of commodity and oil prices continue to pressure Business Performance. The Federal Probe regarding export filings related to its Swiss subsidiary CSARL if proven could have a negative impact. We currently feel the company is fairly valued based on our Performance, Risk and Valuation measures. As business trends become clearer, and CATs cost-cutting and restructuring efforts start to produce positive results, we would anticipate becoming more positive.

penny stock market: trivago N.V. (TRVG)


Advisors’ Opinion:

  • [By Diane Alter]

    Trivago NV (Nasdaq: TRVG) is a German hotel-search company. It priced its initial public offering of 26.1 million American depositary shares (ADSs) at $11 apiece. That was below its projected number of shares and price range. The company had expected to offer 28.5 ADSs at $13 to $15 each.

  • [By Paul Ausick]

    Online travel company Travel BV (NASDAQ: TRVG), better known as trivago, raised $287 million on the sale of 26.1 million American Depositary Shares (ADSs) at $11, below the expected range of $13 to $15. ADSs popped 7.7% for the Friday offering.

penny stock market: TRC Companies Inc.(TRR)


Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of TRC Companies, Inc. (NYSE: TRR) got a boost, shooting up 16 percent to $7.53. TRC posted Q4 earnings of $0.20 per share on revenue of $132.3 million.

penny stock market: Celldex Therapeutics Inc(CLDX)

Advisors’ Opinion:

  • [By Todd Campbell]

    The ability to develop game-changing new drugs that revolutionize patient care could cause shares in Axovant Sciences (NYSE:AXON), Celldex Therapeutics (NASDAQ:CLDX), and Esperion Therapeutics (NASDAQ:ESPR) to soar. However, success may be tough to come by, and that makes investing in these stocks a boom or bust proposition.

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell by 0.57 percent. Meanwhile, top losers in the sector included Amicus Therapeutics, Inc. (NASDAQ: FOLD), down 9 percent, and Celldex Therapeutics, Inc. (NASDAQ: CLDX), down 9 percent.

  • [By WWW.KIPLINGER.COM]

    Celldex Therapeutics, Inc. (CLDX) is the first of the major biotech stocks scheduled to release an update on a pretty important drug this quarter; look for news on Oct. 8 concerning melanoma treatment glembatumumab vedotin. And thats a firm date too. Celldex is slated to present an update on the therapy at the European Society for Medical Oncology Congress.

penny stock market: Biogen Idec Inc(BIIB)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By Brian Orelli]

    While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

penny stock market: Whiting Petroleum Corporation(WLL)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Whiting Petroleum (WLL) has gained 2.9% to $8.30 after reporting a smaller-than-expected loss.

    Weight Watchers International (WTW) has jumped 7.9% to $21.75 after hiring HSN’sMindy Grossman as its new CEO.

  • [By Jon C. Ogg]

    Whiting Petroleum Corporation (NYSE: WLL) saw its shares rocket up by 30.2% to $12.21 on 79.5 million shares on Wednesday. That represents almost 4 times normal trading volume. Whiting Petroleum has a total market cap of $3.5 billion. The company has a consensus analyst price target of $11.39 and a 52-week trading range of $3.35 to $16.62.

  • [By Matthew DiLallo]

    That sell-off in the oil market weighed on financially challenged oil stocks, which will struggle if crude continues dropping. Among the biggest losers were Abraxas Petroleum (NASDAQ:AXAS), Whiting Petroleum (NYSE:WLL), Denbury Resources (NYSE:DNR), California Resources (NYSE:CRC), and Cobalt International Energy (NYSE:CIE).

  • [By Lisa Levin]

    In trading on Friday, energy shares fell 0.62 percent. Meanwhile, top losers in the sector included Teekay Offshore Partners L.P. (NYSE: TOO), down 9 percent, and Whiting Petroleum Corp (NYSE: WLL), down 7 percent.

  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 1.43 percent. Meanwhile, top losers in the sector included Westmoreland Coal Company (NYSE: WLB), down 9 percent, and Whiting Petroleum Corp (NYSE: WLL), down 7 percent.

  • [By Paul Ausick]

    Whiting Petroleum Corp. (NYSE: WLL) posted a new 52-week low of $4.81 on Friday, down about 7.5% compared with Thursday’s closing price of $5.20. The stock’s 52-week high is $13.39. Volume totaled around 21 million shares, about 5% higher than the daily average. The company had no specific news.

penny stock market: Pound/Rand(PX)


Advisors’ Opinion:

  • [By Ben Levisohn]

    The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

    In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

    Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

    Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).

    Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%